• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Vera Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Vera Acquires Global Rights To Dual BAFF/APRIL Inhibitor

    GLOBENEWSWIRE

    Vera Therapeutics to Participate in 43rd J.P. Morgan Conference

    GLOBENEWSWIRE

    Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

    GLOBENEWSWIRE

    Vera Therapeutics Partners with Michigan on Neptune Match & Pioneer

    GLOBENEWSWIRE

    Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics to Participate at Upcoming Investor Conferences

    GLOBENEWSWIRE

    Vera Therapeutics Q3 2024 Financial Results & Business Update

    GLOBENEWSWIRE

    Vera Therapeutics Prices Public Offering of Class A Stock

    GLOBENEWSWIRE

    Vera Therapeutics Proposes Class A Common Stock Offering

    #N/A

    Vera Therapeutics Shows 96-Week eGFR Stabilization in IgAN

    GLOBENEWSWIRE

    Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics Presents ORIGIN Ph 2b Results at ASN Kidney Week

    GLOBENEWSWIRE

    Vera Therapeutics To Host R&D Day On Atacicept Expansion

    GLOBENEWSWIRE

    Vera Therapeutics Completes ORIGIN 3 Trial Enrollment For Atacicept

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq

    GLOBENEWSWIRE

    Vera Therapeutics to Participate at September Investor Conferences

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics Reports Q2 2024 Results And Provides Business Update

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics Appoints David L. Johnson As Chief Operating Officer

    GLOBENEWSWIRE

    Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

    GLOBENEWSWIRE

    Vera To Participate At Goldman Healthcare Conference

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Vera’ atacicept for treatment of IgAN receivesUS FDA breakthrough therapy desig.

    PHARMABIZ

    Vera Therapeutics: FDA Breakthrough Therapy For Atacicept In IgAN

    GLOBENEWSWIRE

    Vera Atacicept IgAN Phase 2b: 72-Week Egfr Hematuria Data At Era Congress

    GLOBENEWSWIRE

    Vera Therapeutics Q1 2024 Results And Business Update

    GLOBENEWSWIRE

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

    MORNINGSTAR

    Vera Announces Presentations at the 61st European Renal Association Congress

    GLOBENEWSWIRE

    Vera Therapeutics Provides Business Update and Reports 4Q

    GLOBENEWSWIRE

    Vera Therapeutics to Participate at 44th Annual TD Cowen Health Care Conference

    GLOBENEWSWIRE

    Vera Therapeutics to Participate in the 6th Annual Biotechnology Conference

    GLOBENEWSWIRE

    Vera Therapeutics Announces Closing of Upsized Public Offering

    GLOBENEWSWIRE

    Vera Announces Pricing of Upsized Public Offering of Class A Common Stock

    GLOBENEWSWIRE

    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

    PRESS RELEASE

    Vera Therapeutics Presents Data Showing eGFR Stabilization in the Phase 2b Trial

    GLOBENEWSWIRE

    Vera Therapeutics to Host In-Person R&D Day in New York

    GLOBENEWSWIRE

    Vera Announces Appointment of Veterans Robert Brenner as CMO

    GLOBENEWSWIRE

    Vera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Vera Therapeutics Reports Third Quarter Financial Results

    GLOBENEWSWIRE

    Vera Presents Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria

    GLOBENEWSWIRE

    Vera Therapeutics Scheduled to Present at November Investor Conferences

    GLOBENEWSWIRE

    Vera Therapeutics to Present Three Posters at the Annual Meeting

    GLOBENEWSWIRE

    Vera Therapeutics Scheduled to Present at September Investor Conferences

    GLOBENEWSWIRE

    Vera Provides Business Update and Reports Second Quarter Financial Results

    GLOBENEWSWIRE

    Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

    GLOBENEWSWIRE

    Vera to Host Presentation of Week 36 Data from Ph2b ORIGIN Trial of Atacicept

    GLOBENEWSWIRE

    Vera to Participate in 44th Annual Goldman Sachs Global Healthcare Conference

    GLOBENEWSWIRE

    Vera Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Atacicept

    GLOBENEWSWIRE

    Vera Therapeutics Reports First Quarter Financial Results

    GLOBENEWSWIRE

    Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior VP

    GLOBENEWSWIRE

    Vera Provides Reports Fourth Quarter and Full Year 2022 Financial Results

    GLOBENEWSWIRE

    Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

    GLOBENEWSWIRE

    Vera Therapeutics Announces Closing of Upsized Public Offering

    GLOBENEWSWIRE

    Roivant, Vera seek $100M+ raises as they look to fund drug hopefuls

    ENDPTS

    Vera Announces Commencement of Public Offering of Class A Common Stock

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.